Why Investors Shouldn't Worry About Sanofi's Poor Quarter
In this video, health-care analyst David Williamson walks investors through Sanofi's rough quarter, and explains why investors need to keep an eye on the bigger picture. Sanofi is dealing with the loss of patent protection on blockbuster Plavix, but investors have a lot to be excited about, especially the potential of diabetes drug Lantus, and also multiple sclerosis drug Aubagio (although it faces steep competition from Biogen). Watch and find out if Sanofi is a stock that should be on your radar.
What macro trend was Warren Buffett referring to when he said, "This is the tapeworm that's eating at American competitiveness?" Find out in our free report: What's Really Eating At America's Competitiveness. You'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.
The article Why Investors Shouldn't Worry About Sanofi's Poor Quarter originally appeared on Fool.com.David Williamsonhas no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.